BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-30@pharmaconomics
DTSTAMP:20260707T025023Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:VRTX Phase 3 — CTX001
DESCRIPTION:Phase 3 trial results for CTX001 in Beta-Thalassemia are due Jun 6\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT05329649\n\nTrack it: https://pharmaconomics.com/e/30
URL:https://pharmaconomics.com/e/30
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VRTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR